Hade Platform Proves Right About FMC Corp (NYSE: FMC) Stock

355 0 0 0 0 0 (0)

We published an article about FMC Corp (NYSE: FMC) on Oct.18 rating FMC stock a Buy which can be found here. So far, of the companies that have reported which we have written articles about, 15 have beat or posted in-line numbers and 3 have missed. We think that's pretty good, now let's take a look at what FMC Corporation did in the third quarter of 2018. (NYSE: FMC) reported revenue of approximately $1.0 billion, an increase of 60 percent year-over-year. Segment results drove the majority of the outperformance, supplemented by a lower tax rate. Revenues from the Agricultural Solutions division shot up 67% year over year to around $924 million. Moreover, the company announced a share repurchase program of $200 million of FMC shares by year-end.

FMC Corp (NYSE: FMC) investment grade on the Hade Platform has risen steadily, making it a Top 30 stock. Ironically, this stability in overall rating happens during a time when the overall market is falling, and as our investment grades as an average have consistently declined for the last four months, effectively predicting a correction.

With overall investment grades still lower, we suggest holding large sums of cash and being very selective when making investment decisions. According to FMC stock’s current grade, it might very well be one of those selective opportunities. Why should you trust our ratings? The Hade Platform has proven over the course of three years through the application of DLAs and artificial intelligence that it consistently outperforms Wall Street consensus estimates (63%) and major benchmarks such as the S&P 500 (250%). Access our premium services and start beating the market.

Free users on Hade Platform can build a watchlist of stocks and access investment grades from our database of more than 4,000 securities. Premium members can access the platform to get an instant look at which stocks rate highest for value, growth, dividend, and which have the greatest short-term momentum, thereby allowing members to identify areas of opportunity. Premium services include interest trends, risk analysis, machine learning predictions, Top 100 stocks, MatriX Portfolio and more.

Register now for the world's best investment ideas


Comments (0)

Recent Updates

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Consumer Healthcare Total Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Consumer Helathcare Other of which Gold Bond Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Polio/Pertussis/Hib Vaccines (incl. Hexaxim/Hexyon, Pentacel, Pentaxim and Imovax) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Influenza Vaccines (incl. Vaxigrip, Fluzone HD, Fluzone, Flublok) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Meningitis/Pneumo Vaccines (incl. Menactra) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Adult Booster Vaccines (incl. Adacel) Revenue